Hint mode is switched on Switch off
For swift navigation between sections

RAPT Therapeutics
LEI 549300MB473BIU78ES48

PDF download

Choose all Reset all
Download Cancel
Organization name
RAPT Therapeutics, Inc.
Country name
USA
Country of registration
USA
Industry
Pharmaceutical Preparation and Biotechnology
Public debt
-
Welcome to Cbonds
New to Cbonds? · Take a 90-second tour of the platform.

Discover what you can do with Cbonds

Everything you need for fixed income research and monitoring.

  • 00:23 Coverage
  • 00:40 Bond screener
  • 00:54 Parameters
  • 01:10 Watchlist, Mobile app
  • 01:15 Excel Add-in
Unlock data Watch full tour

Latest data on

Get access to the largest financial database

Try in 7-days Demo access

Free for company representative

  • Evaluate advanced analytical tools
  • Get full online access to the database
  • Try our powerful bond screener
  • Track bond prices from 400+ sources

Get access to the largest financial database

Representative of the company 7 days FREE trial

Professional access to the data

Private investor

Individual access

Quotes

Request sent
Access denied
Send request
Quotes provided by information providers are indicative in nature

Profile

RAPT Therapeutics, Inc. operates as a pharmaceutical company. The Company offers immunology, small molecule drug discovery, and computational biology services to conquer cancer and allergic inflammatory diseases. RAPT Therapeutics serves customers worldwide.

Awards

News

03/03/2026 RAPT Therapeutics: Completion Of Acquisition Or Disposition Of Assets, Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of Listing, Material Modification To Rights Of Security Holders, Changes In Control Of Registrant, Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
21/01/2026 RAPT Therapeutics' Acquisition by GSK and Its Impact on Stock Performance
20/01/2026 Rapt Therapeutics Acquisition by GSK: A Strategic Move in Immunologic Therapies
19/01/2026 RAPT Therapeutics: Entry Into A Material Definitive Agreement, Regulation Fd Disclosure, Financial Statements And Exhibits
27/10/2025 Guggenheim Initiates Rapt Therapeutics With Buy Rating and $70 Price Target
All organization news

Documentation

IFRS/US GAAP reports

2025
I q eng
II q eng
III q eng
2024
I q eng
II q eng
III q eng
IV q eng
2023
I q eng
II q eng
III q eng
IV q eng
2022
I q eng
II q eng
III q eng
IV q eng
2021
I q eng
II q eng
III q eng
IV q eng
2020
I q eng
II q eng
III q eng
IV q eng
2019
III q eng
IV q eng
Show more Hide
Authorization required
You need to request access

Stocks

Public debt by currencies

Show more Hide

Codes

  • LEI
    549300MB473BIU78ES48
  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • NACE
    *** ***
  • NAICS
    *** ***
  • CIK
    0001673772
  • EIN
    47-3313701
Registration is required to get access.